Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
  • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/33—Fibroblasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/17—Monocytes; Macrophages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
  • A61K40/22—Immunosuppressive or immunotolerising
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
  • A61K40/24—Antigen-presenting cells [APC]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/418—Antigens related to induction of tolerance to non-self
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2500/00—Specific components of cell culture medium
  • C12N2500/70—Undefined extracts
  • C12N2500/80—Undefined extracts from animals
  • C12N2500/84—Undefined extracts from animals from mammals
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2502/00—Coculture with; Conditioned medium produced by
  • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
  • C12N2502/1323—Adult fibroblasts
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2502/00—Coculture with; Conditioned medium produced by
  • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
  • C12N2502/1352—Mesenchymal stem cells
  • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Definitions

• Cardiovascular disease is the most common cause of death in the United States and developed world.
• the human heart suffers loss of viable tissue and contractile function following myocardial infarction (MI) and this leads to heart failure, recurrent hospitalization, arrhythmias and death.
• Ischemic heart failure affects ⁇ 5 million Americans and is the most common reason for hospitalization in the United States. Mortality is high in these patients and similar to that of advanced cancer.
• Standard therapy involves beta-adrenergic and angiotensin II inhibiting medication that block maladaptive neurohormonal pathways, but these drugs are only partially effective and are not universally tolerated.
• Left ventricular assist devices and heart transplant may be offered but device failure, stroke, infection, and organ shortages limit these approaches.
• Local administration of individual angiogenic and cardio-regenerative proteins such as VEGF or gene transcription factors resoundingly failed or created unanticipated toxicities in human cardiovascular disease trials, which have virtually halted further investigations using these approaches.
• Ml macrophages are proinflammatory scavenger cells that are active at times of infection and tissue injury and exhibit potent anti-microbial properties, reminiscent of type 1 T-helper lymphocyte (Thl) responses. Markers of Ml macrophages include, but are not limited to, CD86 and HLA-DR.
• M2 macrophages also called alternatively-activated macrophages, are anti-inflammatory, pro- angiogenic, and pro-regenerative "healing" cells that promote type 2 T-helper lymphocyte (Th2)- like responses, secrete less pro-inflammatory cytokines, and assist resolution of inflammation by trophic factor synthesis and phagocytosis.
• Th2 macrophages include, but are not limited to, CD 163, CD206 and PD-Ll .
• Macrophages can be polarized by their microenvironment to assume different phenotypes associated with different stages of inflammation and healing.
• Certain macrophages are indispensable for wound healing. They participate in the early stages of cell recruitment and of tissue defense, as well as the later stages of tissue homeostasis and repair. (Pollard, Nature Rev. 9:259-270 (2009)). Macrophages derived from peripheral blood monocytes have been used to treat refractory ulcers. (Danon et al., Exp. Gerontol. 32:633-641 (1997); Zuloff-Shani et al., Transfus. Apher. Sci. 30: 163-167 (2004).)
• CD 163 low CD 163 low, CD206 high, CD 16 low, PD-Ll high, PD-L2 high, TGF- ⁇ high, TNF-a low, IL-6 high, IL-10 high, IL-lb high, and Serpine-1 high cardiac fibroblast exosome educated macrophages (CF-EEM).
• CD 163 low CD206 high, CD 16 low, PD-Ll high, PD-L2 high, TGF- ⁇ high, TNF-a low, IL-6 high, IL-10 high, IL-lb high, and Serpine-1 high cardiac fibroblast exosome educated macrophages (CF-EEM).
• BM-EEM Serpine-1 high bone marrow exosome educated macrophages
• a method of treatment to alleviate a condition in a subject in need thereof comprising the step of: administering to the subject a population of macrophages as described herein, wherein the condition is a disease or injury described herein.
• the population of macrophages is administered by injection.
• the population of macrophages is administered by topical application.
• the condition is a cardiovascular disease.
• the condition is ischemic heart failure.
• the macrophages are administered by injection with a pharmaceutically-acceptable carrier.
• the carrier is an injectable cardiac fibroblast-derived extracellular matrix.
• a composition comprising, a population of macrophages as described herein; and a pharmaceutically-acceptable carrier.
• the carrier is selected from the group consisting of liquid, oil, lotion, salve, cream, foam, gel, paste, powder, film, and hydrogel.
• the carrier is an injectable cardiac fibroblast-derived extracellular matrix (CF-ECM).
• the CF-ECM additionally comprises cardiac fibroblast derived exosomes.
• a method for generating an anti-inflammatory macrophage comprising the step of: co-culturing a CD14 + cell with tissue-specific cells or tissue-specific extracellular factors in vitro until the CD14 + cell acquires an antiinflammatory macrophage phenotype.
• the tissue-specific cells are cardiac fibroblasts.
• the extracellular factor is specific to cardiac tissue.
• the extracellular factor is selected from the group consisting of exosomes, micro-vesicles and extracellular matrix.
• a population of anti-inflammatory macrophages produced by the methods described herein.
• the CD14 + cell is a monocyte.
• the tissue-specific cells are selected from the group consisting of bone marrow cells, skin cells, lung cells, pancreatic cells, liver cells, kidney cells, brain cells, endocrine cells, and cells from reproductive organs.
• the tissue-specific extracellular factor is selected from the group consisting of exosomes, micro-vesicles, and extracellular matrix.
• FIG. 1 is a diagram of the formation, release and uptake of various types of extracellular vesicles (EVs) from the secreting cell to the recipient cell.
• EVs extracellular vesicles
• the larger microvesicles bud directly from the plasma membrane, whereas exosomes are smaller vesicles of different sizes which are first formed by the internalization of the cell membrane to produce endosomes. Subsequently, many small vesicles are formed inside the endosome by invagination of sections of the endosome membrane. Such endosomes are called multi-vesicular bodies (MVBs). Finally, the MVBs fuse with the cell membrane and release the intraluminal endosomal vesicles into the extracellular space to become exosomes.
• MVBs multi-vesicular bodies
• mRNAs proteins and various nucleic acids have recently been identified in the exosomal lumen, including mRNAs, microRNAs (miRNAs), and other non- coding RNAs (ncRNAs). These internal components can be taken up by neighboring cells or distant cells and modulate recipient cell phenotype and activity.
• Image source Lieff, J. "Vesicle Transport Information," Searching for the Mind, January 19, 2014, jonlieffmd.com.
• FIGS. 2A-2B show exosome size distribution characterization using an IZON nanoparticle system.
• A shows characterization of mesenchymal stem cell exosomes, with a protein concentration of 2.2mg/ml, an RNA concentration of 61.8ng/ml, a mean particle diameter of 123 nm, a mode particle diameter of 93 nm, and a concentration of 6.0xlO u particles/ml.
• (B) shows characterization of cardiac fibroblast exosomes, with a volume of 25 ⁇ ., a protein concentration of 0.17mg/ml, an RNA concentration of 13.6ng ⁇ l, an A260/280 of 1.45, a mean particle diameter of 165.9 nm, and a concentration of 3.2xlO u particles/ml.
• FIGS. 3A-3B show transmission electron microscopy images of (A) mesenchymal stem cell (MSC) exosomes and (B) cardiac fibroblast (CF) exosomes.
• MSC mesenchymal stem cell
• CF cardiac fibroblast
• FIGS. 4A-4B depict testing of exosome functionality by lipophilic dye transfer by mesenchymal stem cell exosomes into endothelial cells.
• FIGS. 5A-5J show the surface marker profile of macrophages educated with exosomes derived from bone marrow and cardiac fibroblasts. Levels of expression profile markers were measured by flow cytometry comparing macrophages (control) with educated macrophages generated by co-cultivation of monocytes with BM-MSCs (BM-MEM), exosomes derived from bone marrow (BM-EEM), or exosomes derived from cardiac fibroblasts (CF- EEM).
• BM-MEM BM-MSCs
• BM-EEM exosomes derived from bone marrow
• CF- EEM exosomes derived from cardiac fibroblasts
• FIGS. 6A-6D show the Ml surface marker profile of macrophages educated with exosomes derived from bone marrow (BM-EEM), or exosomes derived from cardiac fibroblasts (CF-EEM).
• BM-EEM bone marrow
• CF-EEM cardiac fibroblasts
• levels of Ml expression profile markers were measured by flow cytometry comparing macrophages (control) with macrophages educated by co-cultivation of monocytes with BM-MSCs (BM-MEM) or with exosomes derived from bone marrow (BM-EEM), or with exosomes derived from cardiac fibroblasts (CF-EEM).
• CD86 mean fluorescence intensity (MFI) is statistically lower in CF-EEM compared to BM-EEM.
• CD86 is the co-stimulatory signal for T-cell activation and HLA-DR is the ligand for T-cell receptor.
• FIGS. 7A-7E compare the canonical M2 surface marker expression in macrophages educated by co-culture with exosomes from BM-MSCs (BM-EEM) or exosomes derived from macrophages (macrophage-EEM). Exosomes from macrophage cultures do not induce an M2 phenotype in macrophages.
• FIG. 8 shows the expression of CD206 in cardiac fibroblast extracellular matrix (CF- ECM) educated macrophages.
• FIG. 9 depicts differences in gene expression of various cytokines, measured by qPCR.
• FIGS. 10A-10B depict the co-cultivation of unstimulated T-cells with either macrophages or BM-EEMs.
• the BM-EEMs do not cause activation and proliferation of T-cells.
• FIGS. 11A-11B depict in vitro functional assays of BM-EEMs. After T-cell activation, MSCs are known to suppress T-cell proliferation. BM-EEMs are more suppressive than uneducated macrophages.
• FIGS. 12A-12E show that CF-EEM delivered with cardiac extracellular matrix significantly improves cardiac function post myocardial infarction. Comparison between sham and CF-EEM/matrix treated rats post myocardial infarction demonstrates significant improvements in systolic pressures, reduced deleterious remodeling and increased cardiac contractility (measured as end systolic-pressure volume relationship, ESPVR). Significant angiogenesis was observed within the infarcted area (scar) in the treated animals as indicated by white arrows. [0030] FIG. 13 compares qPCR gene expression in BM-MEMs vs BM-EEMs of various pro- and anti-inflammatory markers. To demonstrate the fold difference comparison between the two sets, the expression levels in the BM-MEM were set to a value of 1.
• FIG. 14 compares qPCR gene expression in BM-EEMs, CF-EEMs and uneducated macrophages (control) of various pro- and anti-inflammatory markers. To demonstrate the fold difference comparison between all three sets, the expression levels in the control macrophages were set to a value of 1.
• FIG. 15 shows cardiac fibroblast characterization.
• Cardiac fibroblasts have a unique surface marker and internal marker phenotype.
• Human cardiac fibroblasts differentially express CD90, CD34, SUSD2, w67c, and TNAP by flow cytometry analysis compared to MSCs and dermal fibroblasts.
• cardiac fibroblasts also express GATA 4, which is not expressed in MSCs or dermal fibroblasts.
• FIG. 16 shows characterization of cardiac fibroblast extracellular vesicles.
• Cardiac fibroblast exosomes were characterized using a Thermo NanoDrop spectrophotometer for protein determination and approximate RNA concentration by direct absorbance; exosomes were not lysed, stained, or RNA extracted prior to measurements.
• Particle diameter and concentration were assessed by tunable resistive pulse sensing (TRPS; (qNano, Izon Science Ltd) using a NP150 nanopore membrane at a 47 mm stretch.
• TRPS tunable resistive pulse sensing
• the concentration of particles was standardized using multi -pressure calibration with 110 nm carboxylated polystyrene beads at a concentration of 1.1 x 10 13 parti cles/mL.
• FIG. 17 shows cardiac fibroblast total RNA isolation.
• Exosomes from the cardiac fibroblasts were processed for total RNA isolation using the SeraMir Exosome RNA Purification Column kit (Cat #RA808A-1, System Biosciences, Palo Alto, CA) according to the manufacturer's instructions.
• 1 ⁇ of the final RNA eluate was used for measurement of small RNA concentration by Agilent Bioanalyzer Small RNA Assay using Bioanalyzer 2100 Expert instrument (Agilent Technologies, Santa Clara, CA).
• Cardiac fibroblast exosomes derived from three donors were compared by RNA sequencing for similarities. Briefly, the expected counts per gene were estimated in each sample using RSEM.
• the counts were filtered keeping only those genes that had at least one expected count (per gene) in all three samples.
• TMM trimmed method of means
• FIG. 18 shows CF-EEM secretome cytokine analysis characterization.
• CF-EEMs have a unique secretome compared to non-stimulated macrophages (PBS) and bone marrow EEMs (BM-EEM).
• BM-EEMs secrete EGF, compared to control macrophages (PBS) or BM-EEMS while BM-EEMs secrete significantly more GRO compared to CF-EEMs and control macrophages.
• FIGS. 19A-19C show characterization of CF-ECM-EMs.
• Human macrophages were cultured on plastic, gelatin or CF-ECM for 3 days then removed from the surfaces and flow cytometry was used to analyze surface marker expression. Macrophages had a significantly higher expression (by mean fluorescent intensity) of CD 14, CD 163, CD206 and PDL (FIG. 19C). In addition, macrophages had significantly lower expression of inflammatory markers CD68 and HLA-DR (FIG. 19B). Macrophages cultured on cardiac fibroblast derived extracellular matrix (CF-ECM) (or CF-ECM-EMs) have a unique anti-inflammatory phenotype. CF-ECM-EMs have significantly lower expression of CD86 and HLA-DR, while PDL-1 expression is significantly increased (FIGS. 19A and 19C). PDL-1 is believed to play a major role in suppressing the immune system.
• CF-ECM cardiac fibroblast derived extracellular matrix
• FIG. 20 represents a translation pathway of generating and using tissue-specific macrophages.
• A tissue source
• cells such as fibroblasts, tissue progenitor cells and others are harvested using biopsy or organ procurement or differentiated from pluripotent stem cells (B).
• Tissue-specific educated macrophages are expected to be phenotypically and functionally unique with unique cytokine, RNA, surface marker and functional expression. These tissue-specific educated macrophages can be delivered to a subject in need of treatment systemically or directly into injured tissues. Methods of delivery can include intravenous infusion, intravascular infusion, percutaneous injection, surgical injection, topical administration or any other delivery method described herein. Tissue-specific educated macrophages are expected to restore injured tissues as demonstrated in a variety of animal models (E) and clinical applications (F) in a tissue-specific manner.
• E animal models
• F clinical applications
• the present disclosure broadly relates to an anti-inflammatory tissue-specific educated macrophage as well as methods for making and using such a macrophage.
• CD14 + monocytes or macrophages are co-cultured with tissue-specific cells or extracellular factors to yield tissue-specific educated macrophages.
• Educated macrophages generated by the methods of the present invention may be used to treat or prevent a disease by administration of the educated macrophages to a subject in need thereof.
• tissue-specific anti-inflammatory and tissue reparative macrophages generated ex vivo by co-culturing a CD14 + monocyte or macrophage with a tissue-specific cell or with an extracellular factor.
• Educated macrophages generated by co-culture of this type are generally characterized as CD 163 low, CD206 high, CD16 low, PD-L1 high, PD-L2 high, TGF- ⁇ high, TNF-a low, and IL-lb high compared to non- educated macrophages.
• Levels of characteristic markers may be measured by flow cytometry, gene expression analysis, or other means known in the art.
• the educated macrophages are specific to cardiac cells and are generated by co-culturing CD14 + monocytes or macrophages with cardiac-specific cells or extracellular factors. In one embodiment, the educated macrophages are specific to bone marrow cells and are generated by co-culturing CD14 + monocytes or macrophages with bone-marrow-specific cells or extracellular factors.
• CD14 + cells are co-cultured with cells from a specific tissue ("tissue-specific cells") or with tissue-specific extracellular factors to yield educated macrophages.
• tissue-specific cells tissue-specific cells
• Methods of co-culturing CD14 + cells with mesenchymal stem cells (MSCs) to generate MSC-educated macrophages have been described, see U.S. Patent No. 8,647,678 and U.S. Patent Publication No. 2016/0082042, both incorporated herein by reference.
• CD14 + cells are co-cultured ex vivo with tissue-specific cells or tissue-specific extracellular factors in any culture medium known in the art suitable for survival and growth of the co-culture components.
• the co-cultures may be maintained for between 0-28 days to generate educated macrophages.
• Co-cultures may generate educated macrophages with the desired immuno-phenotype after 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 20, 23, 25 or more than 26 days.
• co-cultures yield educated macrophages after 10 days.
• co-cultures yield educated macrophages after 5 days.
• co-cultures yield educated macrophages after 1 day.
• tissue-specific cells or tissue-specific extracellular factors are subjected to additional purification steps prior to use in co-culture to obtain educated macrophages.
• Tissue-specific cells or extracellular factors can be added in a single dose or repeated doses to CD14 + cultures to generate educated macrophages.
• monocytes or macrophages can be co- cultured with tissue-specific cells or tissue-specific extracellular factors such that the cells are in direct physical contact.
• the co-culture components can be placed in sub- compartments that are in fluid communication but separated by a semi-permeable membrane.
• the semi-permeable membrane allows the exchange of soluble medium components and factors secreted by the cells but is impenetrable for the cells themselves.
• the pores within the semipermeable membrane are sufficiently small to prevent cell penetration but large enough to allow soluble medium components to pass across the membrane, and are typically are between 0.1-1.0 ⁇ , but other pore sizes can be suitable.
• educated macrophages can be isolated from the co-culture using flow cytometry or magnetic based sorting. Educated macrophages can be maintained in culture in any medium that supports macrophages in vitro. Also, educated macrophages can be stored using methods known in the art including, but not limited to, refrigeration, cryopreservation, vitrification, lyophilization, and immortalization.
• CD14 + cell refers to a monocyte or a macrophage.
• CD14 + cells can be derived from any suitable source. The skilled artisan will appreciate the advantageous efficiency of generating macrophages from peripheral blood monocytes for co-cultures. Alternatively, macrophages can also be isolated from cellular outgrowth of a tissue sample taken from an individual. Peripheral blood monocytes can be cultured for various times and under various conditions before co-culture or can be added to the exosomes or extracellular matrix directly for co-cultures. In one embodiment, monocytes are harvested from a subject by leukapheresis. In one embodiment, CD14+ cells are isolated from peripheral blood.
• CD14+ cells are isolated from peripheral blood of a patient who has first been treated with an agent including but not limited to G-CSF, GM-CSF, MozobilTM (plerixafor injection) and the like to mobilize cells into the peripheral blood.
• CD14+ cells are isolated from peripheral blood with G-CSF stimulation.
• CD14+ cells are isolated from bone marrow aspirates.
• CD14+ cells are isolated from tissues or organs such as heart.
• CD14+ cells are derived from pluripotent stem cells such as embryonic stem cells or induced pluripotent stem cells.
• macrophage refers to a mononuclear phagocyte characterized by the expression of CD14 and lack of expression of dendritic or mesenchymal cell markers.
• nonuclear leukocytes or “monocytes” are white blood cells that can differentiate into macrophages when recruited to tissues and can influence both innate and adaptive immune system.
• “high” means that the cells are characterized by higher expression of a particular cytokine compared to control macrophages cultured without tissue-specific cells or extracellular factors.
• IL-6 high indicates that macrophages co-cultured with tissue-specific cells or extracellular factors express higher amounts of IL-6 than macrophages that have not been co-cultured with tissue-specific cells or extracellular factors.
• low means that the cells are characterized by lower expression of a particular cytokine.
• “IL-12 low” indicates that macrophages co-cultured with tissue-specific cells or extracellular factors express lower amounts of IL-12 than macrophages that have not been co-cultured with tissue-specific cells or extracellular factors.
• “Low” can also mean that the expression levels are below the detection limit.
• monocytes, macrophages, tissue-specific cells, and extracellular factors employed in methods described herein can be cultured or co-cultured in any medium that supports their survival and growth.
• the medium is serum free- medium including but not limited to X-VIVO 15 and STEMPRO serum-free media.
• the medium uses human platelet lysates to replace the human AB serum in the macrophage medium. Co-cultures do not require the addition of cytokines.
• Tissue-specific cells, extracellular factors and macrophages can be autologous, syngeneic, allogeneic, or third party with respect to one another.
• mesenchymal stem cells refers to the fibroblast-like cells that reside within virtually all tissues of a postnatal individual.
• mesenchymal stem cells or MSCs are also known in the art as mesenchymal stromal cells, marrow stromal cells, multipotent stromal cells, and perhaps by other names.
• An MSC within the scope of this disclosure is any cell that can differentiate into osteoblasts, chondrocytes, and adipocytes.
• MSC within the scope of this disclosure is positive for the expression of CD105, CD73, and CD90 while lacking expression of CD45, CD34, CD14 or CDl lb, CD79a or CD19, and HLA-DR surface molecules.
• CD45, CD34, CD14 or CDl lb, CD79a or CD19, and HLA-DR surface molecules While these markers are known to characterize MSCs derived from most tissues, it is understood in the art that MSCs from some sources could exhibit differences in cell surface marker expression.
• MSCs provide the stromal support tissue for hematopoietic stem cells. MSCs can differentiate into cells of the mesenchymal lineage. In some embodiments, MSCs are co-cultured with CD14 + cells to generate MSC educated macrophages (referred to herein as MEMs).
• the tissue-specific cells are bone marrow mesenchymal stem cells (referred to herein as BM-MSCs).
• BM-MSCs are co-cultured with CD14 + cells to generate bone marrow specific educated macrophages (referred to herein as BM-MEM).
• the tissue-specific cells are cardiac fibroblast cells (referred to herein as CF).
• CF are co-cultured with CD14 + cells to generate cardiac fibroblast educated macrophages (referred to herein as CF-EM).
• CFs, MSCs, BM-MSCs, and other cells described herein for use in the methods or compositions of the present invention may be derived or isolated from any suitable source.
• CFs are isolated from donor heart tissue.
• CFs are biopsied from a patient with a disease or injury as described herein.
• CFs are differentiated from embryonic or induced pluripotent stem cells.
• MSCs are isolated from cardiac tissue.
• MSCs are isolated from tissue such as bone marrow and lung tissue.
• MSCs are differentiated from embryonic or induced pluripotent stem cells.
• extracellular factors refers to extracellular vesicles, exosomes, micro-vesicles, extracellular matrix compositions, isolated extracellular matrix components and fragments or derivatives thereof, exosomes purified from an extracellular matrix, and combinations thereof. Extracellular factors are used in co-culture with CD14 + cells to educate macrophages in a tissue-specific manner. Tissue-specific extracellular factors are derived or isolated for a cell from a specific tissue of interest. As used herein, “extracellular vesicles” refers to both exosomes and micro-vesicles.
• exosomes refer to small lipid vesicles released by a variety of cell types. Exosomes are generated by inward- or reverse budding, resulting in particles that contain cytosol and exposed extracellular domains of certain membrane-associated proteins (Stoorvogel et al., Traffic 3 :321-330 (2002)). Methods of preparing exosomes from cells are known in the art. See, for example, Raposo et al., J. Exp. Med. 183 : 1161 (1996). In one method, exosomes are recovered from conditioned culture medium by centrifugation.
• exosomes are co-cultured with macrophages to generate tissue-specific educated macrophages with increased specificity for the tissues from which the exosomes were derived.
• Exosomes suited for use in the methods can be derived fresh or can be previously frozen aliquots kept as a composition, thawed, and added in a single dose or repeated doses to CD14 + cultures to generate educated macrophages.
• exosome preparations may also include micro-vesicles.
• tissue-specific exosomes are known to express surface markers of their tissue of origin which may result in tissue-specific educated macrophages that are targeted to the tissue of origin.
• Exosomes from the tissue of interest for example a damaged tissue targeted for repair, are likely to contain tissue-specific translational or post translational factors, internal nucleic acids, and proteins that are specific to tissue of interest and superior for repair of said tissue.
• Exosomes can have, but are not limited to, a diameter of about 10-300nm. In some embodiments, the exosomes can have, but are not limited to, a diameter between 20-250nm, 30- 200nm or about 50-150nm. Exosomes may be isolated or derived from any cell type that resides in the target tissue of interest which can be isolated and cultured for a period of time appropriate for the isolation of exosomes.
• the exosomes are derived from bone marrow mesenchymal stem cells.
• Exosomes derived from bone marrow MSCs are co-cultured with CD14 + cells to generate bone marrow exosome-educated macrophages (referred to herein as BM-EEM).
• BM-EEM bone marrow exosome-educated macrophages
• the BM-EEMs are CD 163 and CD 16 low and CD206, PDL-1, and PDL-2 high.
• BM-EEMs are TGF, TNF, and ILlb high and IL6, serpine and VEGF low compared to the MEMs.
• the exosomes are derived from cardiac fibroblasts (referred to herein as CF-EVs).
• CF-EVs are co-cultured with CD14 + cells to generate cardiac fibroblast exosome-educated macrophages (referred to herein as CF-EEM).
• BM-EEMs When comparing external surface markers of MEMs to BM-EEMs by flow cytometry the BM-EEMs are CD 163 and CD 16 low and CD206, PDL-1, and PDL-2 high.
• BM-EEMs When comparing gene expression by qPCR BM-EEMs are TGF, TNF, and ILlb high and IL6, serpine and VEGF low compared to the MEMs.
• BM-EEMs TGF, TNF, and ILlb high and IL6, serpine and VEGF low compared to the MEMs.
• the expression profiles of the BM-EEMs and the CF-EEMs There are distinctions between the expression profiles of the BM-EEMs and the CF-EEMs.
• CD206 Comparing the BM-EEM profile to CF-EEM profile by flow cytometry, CD206 is slightly lower, as is CD 16 in the CF-EEMs, but both PD-L1 and PDL-2 are higher compared to the BM-EEMs. Slight differences are also seen in gene expression by qPCR, most notably in the expression of IL-6.
• Table 1 Characteristic surface marker phenotypes and cytokine growth factor profiles of some embodiments of the educated macrophages described herein.
• the exosomes may be embedded within a cardiac fibroblast- derived extracellular matrix (CF-ECM) for use in a co-culture with CD14 + cells.
• the embedded matrix is created by saturating CF-ECM with CF-exosomes and vacuum drying the combination material resulting in the deposition of exosomes in the CF-ECM.
• CD14 + cells are co-cultured with cardiac fibroblast extracellular matrix to generate cardiac fibroblast extracellular matrix educated macrophages (referred to herein as CF-ECM-EM).
• CF-ECM-EM cardiac fibroblast extracellular matrix educated macrophages
• CD14+ cells are co-cultured with exosomes isolated from a cardiac fibroblast extracellular matrix to generate cardiac fibroblast ECM exosome educated macrophages (CF-ECM-EM).
• CF-ECM cardiac fibroblast-derived extracellular matrix
• CF-ECM cardiac fibroblast-derived extracellular matrix
• the CF-ECM is an engineered CF-ECM as described in U.S. Patent No. 8,802,144 and U.S. Patent Publication No. US 2016/0354447, both of which are incorporated herein by reference.
• An engineered CF-ECM can include structural proteins fibronectin, collagen type I, collagen type III, and elastin, and other structural proteins.
• an engineered CF-ECM includes the structural protein collagen type V.
• fibronectin molecules make up from 60% to 90%, or from 70% to 90%, or from 80% to 90%, of the structural protein molecules present in the engineered CF-ECM.
• the engineered CF-ECM Before it is fragmented or lyophilized, the engineered CF-ECM has a thickness of 20- 500 ⁇ . In some embodiments, the unfragmented CF-ECM has a thickness range of 30-200 ⁇ or of 50-150 ⁇ . In some embodiments, more than 80% of the structural protein molecules are fibronectin molecules.
• the structural proteins of the engineered CF-ECM are not chemically cross-linked.
• the CF-ECM may include one or more matricellular proteins, such as growth factors and cytokines, as well as other substances.
• matricellular proteins such as growth factors and cytokines, as well as other substances.
• other proteins that may be found in the cardiac ECM include latent transforming growth factor beta 1 (LTGFP-l), latent transforming growth factor beta 2 (LTGFP- 2), connective tissue growth factor (CTGF), secreted protein acidic and rich in cysteine (SPARC), versican core protein (VCAN), galectin 1, galectin 3, matrix gla protein (MGP), sulfated glycoprotein 1, protein-lysine 6-oxidase, and biglycan.
• LGFP-l latent transforming growth factor beta 1
• LGFP- 2 latent transforming growth factor beta 2
• CTGF connective tissue growth factor
• SPARC secreted protein acidic and rich in cysteine
• VCAN versican core protein
• Glectin 1 galectin 3
• MGP matrix gla protein
• the ECM may optionally include one or more of transforming growth factor beta 1 (TGFP-l), transforming growth factor beta 3 (TGFP-3), epidermal growth factor-like protein 8, growth/differentiation factor 6, granulins, galectin 3 binding protein, nidogen 1, nidogen 2, decorin, prolargin, vascular endothelial growth factor D (VEGF-D), Von Willebrand factor Al, Von Willebrand factor A5 A, matrix metalloprotease 14, matrix metalloprotease 23, platelet factor 4, prothrombin, tumor necrosis factor ligand superfamily member 11, and glia derived nexin.
• TGFP-l transforming growth factor beta 1
• TGFP-3 transforming growth factor beta 3
• epidermal growth factor-like protein 8 growth/differentiation factor 6
• galectin 3 binding protein galectin 3 binding protein
• nidogen 1, nidogen 2, decorin prolargin
• VEGF-D vascular endothelial growth factor D
• the engineered CF-ECM is decellularized, and is substantially devoid of intact cardiac fibroblast cells.
• the CF-ECM may be seeded using methods that are known in the art with one or more cells that are therapeutic for cardiac disease or injury. Examples of therapeutic cells types that could be used to seed the CF-ECM bioscaffold include without limitation CF, CD14+ monocytes, macrophages, MSCs, CF-EEMs, BM-EEMs, BM- MEM, CF-ECM-EMs or combinations thereof.
• educated macrophages are administered to a subject in need of thereof.
• Subjects in need of treatment include those already having or diagnosed with a disease or injury as described herein or those who are at risk of developing a disease or injury as described herein.
• a disease or injury of the present invention may include, but is not limited to, conditions associated with aberrant, uncontrolled, or inappropriate inflammation, cardiovascular disease, atherosclerosis, cytokine release syndrome (CRS), and other disorders associated with cytokine storm such as adult respiratory distress syndrome (ARDS), and severe acute respiratory syndrome (SARS).
• CRS is a rapid and massive release of cytokines into the bloodstream which can lead to high fevers and cardiac dysfunction, and is frequently observed following administration of immunotherapeutics (e.g., therapeutic mAb infusions) and following adoptive T-cell therapies (e.g., administration of T-cells engineered to express CARs).
• the methods provided herein improve the chance for the subject to receive therapeutic benefit from an immunotherapy while minimizing the risk for life threatening complications of CRS and other cytokine- associated toxicities.
• Cardiovascular disease may refer to, but is not limited to, coronary heart disease, heart failure associated conditions (such as ischemic cardiomyopathy and non-ischemic cardiomyopathies such as infiltrative cardiomyopathy, inflammatory cardiomyopathy, myocarditis, valvular cardiomyopathy), chronic ischemia with preserved ejection fraction (such as chronic angina due to atherosclerosis), recent myocardial infarction or recent myocardial ischemia such as acute coronary syndrome, arrhythmia associated conditions such as conduction disturbances and tachyarrhythmias.
• ischemic cardiomyopathy and non-ischemic cardiomyopathies such as infiltrative cardiomyopathy, inflammatory cardiomyopathy, myocarditis, valvular cardiomyopathy
• chronic ischemia with preserved ejection fraction such as chronic angina due to atherosclerosis
• recent myocardial infarction or recent myocardial ischemia such as acute coronary syndrome
• arrhythmia associated conditions such as conduction disturbances and tachyar
• a disease or injury of the present invention includes disease or injury of the lung such as, but not limited to, chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis obliterans, and the like.
• COPD chronic obstructive pulmonary disease
• a disease or injury of the present invention includes disease or injury of the vasculature such as, but not limited to, peripheral artery disease and the like.
• a disease or injury of the present invention includes disease or injury of the bone marrow such as, but not limited to, graft vs. host disease, bone marrow failure, and the like.
• a disease or injury of the present invention includes disease or injury of the skin such as, but not limited to, burns, trauma, ischemic ulcers, neuropathic ulcers, and the like.
• a disease or injury of the present invention includes disease or injury of the pancreases such as, but not limited to, diabetes.
• a disease or injury of the present invention includes disease or injury of the liver such as, but not limited to, cirrhosis, liver failure, and the like.
• a disease or injury of the present invention includes disease or injury of the kidney such as, but not limited to, acute and chronic renal failure.
• a disease or injury of the present invention includes disease or injury of the brain such as, but not limited to, stroke, neurodegeneration, neurodevelopmental diseases, and the like.
• a disease or injury of the present invention includes disease or injury of the endocrine organs such as, but not limited to, hormone deficiency or endocrine organ inflammation.
• a disease or injury of the present invention includes disease or injury of the reproductive organs such as, but not limited to, infertility, hormone imbalance, menopause, premature aging, and the like.
• a disease or injury of the present invention includes aging or a disease or injury associated with the normal human aging process.
• treating the disease or injury includes, without limitation, alleviating one or more clinical indications, decreasing inflammation, reducing the severity of one or more clinical indications of the disease or injury, diminishing the extent of the condition, stabilizing the subject's disease or injury (i.e., not worsening), delay or slowing, halting, or reversing the disease or injury and bringing about partial or complete remission of the disease or injury. Treating the disease or injury also includes prolonging survival by days, weeks, months, or years as compared to prognosis if treated according to standard medical practice not incorporating treatment with educated macrophages.
• Subjects in need of treatment can include those already having or diagnosed with a disease or injury as described herein as well as those prone to, likely to develop, or suspected of having a disease or injury as described herein.
• Pre-treating or preventing a disease or injury according to a method of the present invention includes initiating the administration of a therapeutic (e.g., human educated macrophages) at a time prior to the appearance or existence of the disease or injury, or prior to the exposure of a subject to factors known to induce the disease or injury.
• a therapeutic e.g., human educated macrophages
• preventing the disease or injury comprises initiating the administration of a therapeutic (e.g., educated macrophages) at a time prior to the appearance or existence of the disease or injury such that the disease or injury, or its symptoms, pathological features, consequences, or adverse effects do not occur.
• a method of the invention for preventing the disease or injury comprises administering educated macrophages to a subject in need thereof prior to exposure of the subject to factors that influence the development of the disease or injury.
• the terms "subject” or “patient” are used interchangeably and can encompass any vertebrate including, without limitation, humans, mammals, reptiles, amphibians, and fish.
• the subject or patient is a mammal such as a human, or a mammal such as a domesticated mammal, e.g., dog, cat, horse, and the like, or livestock, e.g., cow, sheep, pig, and the like.
• livestock e.g., cow, sheep, pig, and the like.
• the subject is a human.
• the phrase "in need thereof indicates the state of the subject, wherein therapeutic or preventative measures are desirable.
• a state can include, but is not limited to, subjects having a disease or injury as described herein or a pathological symptom or feature associated with a disease or injury as described herein.
• a method of treating or preventing a disease or injury as described herein comprises administering a pharmaceutical composition comprising a therapeutically effective amount of educated macrophages as a therapeutic agent (i.e., for therapeutic applications).
• a pharmaceutical composition refers to a chemical or biological composition suitable for administration to a mammal.
• compositions appropriate for such therapeutic applications include preparations for parenteral, subcutaneous, transdermal, intradermal, intramuscular, intracoronarial, intramyocardial, intrapericardial, intraperitoneal, intravenous (e.g., injectable), intraparenchymal, intrathecal, or intratracheal administration, such as sterile suspensions, emulsions, and aerosols.
• Intratracheal administration can involve contacting or exposing lung tissue, e.g., pulmonary alveoli, to a pharmaceutical composition comprising a therapeutically effective amount of educated macrophages, alone or in combination with tissue-specific ECM or extracellular vesicles.
• compositions appropriate for therapeutic applications may be in admixture with one or more pharmaceutically-acceptable excipients, diluents, or carriers such as sterile water, physiological saline, glucose or the like.
• pharmaceutically-acceptable excipients such as sterile water, physiological saline, glucose or the like.
• educated macrophages described herein can be administered to a subject as a pharmaceutical composition comprising a carrier solution.
• Formulations may be designed or intended for oral, rectal, nasal, topical or transmucosal (including buccal, sublingual, ocular, vaginal and rectal) and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intraperitoneal, intrathecal, intraocular intraparenchymal, intrathecal and epidural) administration.
• parenteral including subcutaneous, intramuscular, intravenous, intradermal, intraperitoneal, intrathecal, intraocular intraparenchymal, intrathecal and epidural
• parenteral including subcutaneous, intramuscular, intravenous, intradermal, intraperitoneal, intrathecal, intraocular intraparenchymal, intrathecal and epidural
• parenteral including subcutaneous, intramuscular, intravenous, intradermal, intraperitoneal, intrathecal, intraocular intraparenchymal, intrathecal and epidural
• aqueous and non-aqueous liquid or cream formulations are delivered by a parenter
• compositions may be present as an aqueous or a non-aqueous liquid formulation or a solid formulation suitable for administration by any route, e.g., oral, topical, buccal, sublingual, parenteral, aerosol, a depot such as a subcutaneous depot or an intraperitoneal, intraparenchymal or intramuscular depot.
• pharmaceutical compositions are lyophilized.
• pharmaceutical compositions as provided herein contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
• compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
• the preferred route may vary with, for example, the subject's pathological condition or weight or the subject's response to therapy or that is appropriate to the circumstances.
• the formulations can also be administered by two or more routes, where the delivery methods are essentially simultaneous or they may be essentially sequential with little or no temporal overlap in the times at which the composition is administered to the subject.
• Suitable regimes for initial administration and further doses or for sequential administrations also are variable, may include an initial administration followed by subsequent administrations, but nonetheless, may be ascertained by the skilled artisan from this disclosure, the documents cited herein, and the knowledge in the art.
• educated macrophages may be optionally administered in combination with one or more additional active agents.
• active agents include anti-inflammatory, anti- cytokine, analgesic, antipyretic, antibiotic, and antiviral agents, as well as growth factors and agonists, antagonists, and modulators of immunoregulatory agents (e.g., TNF-a, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-18, IFN-a, IFN- ⁇ , BAFF, CXCL13, IP- 10, VEGF, EPO, EGF, HRG, Hepatocyte Growth Factor (HGF), Hepcidin, including antibodies reactive against any of the foregoing, and antibodies reactive against any of their receptors).
• immunoregulatory agents e.g., TNF-a, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-18, IFN-a, IFN- ⁇ , BAFF, CXCL13, IP- 10, VE
• educated macrophages can be administered either simultaneously or sequentially with other active agents.
• victims of ischemic heart injury may simultaneously receive educated macrophages and a blood thinner such as heparin, a glycoprotein Ilb/IIIa inhibitor or a P2Y12 inhibitor for a length of time or according to a dosage regimen sufficient to support recovery and to treat, alleviate, or lessen the severity of the ischemic heart injury.
• educated macrophages of the present invention may also be administered to a patient simultaneously receiving a stent, bypass graft, ventricular assist device, or other forms of cell therapy.
• the educated macrophages are administered prior to, simultaneously with, or following the administration of a second cell therapy such as to improve or enhance engraftment, survival or function of the administered cells.
• educated macrophages are administered to a subject in need thereof using an infusion, topical application, surgical transplantation, or implantation.
• administration is systemic.
• educated macrophages can be provided to a subject in need thereof in a pharmaceutical composition adapted for intravenous administration to subjects.
• compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. The use of such buffers and diluents is well known in the art.
• the composition may also include a local anesthetic to ameliorate any pain at the site of the injection.
• the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a cryopreserved concentrate in a hermetically sealed container such as an ampoule indicating the quantity of active agent.
• a cryopreserved concentrate in a hermetically sealed container such as an ampoule indicating the quantity of active agent.
• the composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
• an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
• compositions comprising human educated macrophages are cryopreserved prior to administration.
• Therapeutically effective amounts of educated macrophages are administered to a subject in need thereof.
• An effective dose or amount is an amount sufficient to effect a beneficial or desired clinical result.
• the effective dose or amount, which can be administered in one or more administrations is the amount of human educated macrophages sufficient to elicit a therapeutic effect in a subject to whom the cells are administered.
• an effective dose of educated macrophages is about 1 x 10 5 cells/kilogram to about 10 x 10 9 cells/kilogram of body weight of the recipient (e.g., 1 x 10 5 cells/kilogram, 5 x 10 5 cells/kilogram, 1 x 10 6 cells/kilogram, 5 x 10 6 cells/kilogram, 1 x 10 7 cells/kilogram, 5 x 10 7 cells/kilogram, 1 x 10 8 cells/kilogram, 5 x 10 8 cells/kilogram, or 1 x 10 9 cells/kilogram).
• 1 x 10 5 cells/kilogram e.g., 1 x 10 5 cells/kilogram, 5 x 10 5 cells/kilogram, 1 x 10 6 cells/kilogram, 5 x 10 6 cells/kilogram, 1 x 10 7 cells/kilogram, 5 x 10 7 cells/kilogram, 1 x 10 8 cells/kilogram, or 1 x 10 9 cells/kilogram.
• Effective amounts will be affected by various factors which modify the action of the cells upon administration and the subject's biological response to the cells, e.g., severity of ischemic heart failure, type of damaged tissue, the patient's age, sex, and diet, the severity of inflammation, time of administration, and other clinical factors.
• Therapeutically effective amounts for administration to a human subject can be determined in animal tests and any art-accepted methods for scaling an amount determined to be effective for an animal for human administration. For example, an amount can be initially measured to be effective in an animal model (e.g., to achieve a beneficial or desired clinical result). The amount obtained from the animal model can be used in formulating an effective amount for humans by using conversion factors known in the art. The effective amount obtained in one animal model can also be converted for another animal by using suitable conversion factors such as, for example, body surface area factors.
• therapeutically effective amounts of educated macrophages can be determined by, for example, measuring the effects of a therapeutic in a subject by incrementally increasing the dosage until the desired symptomatic relief level is achieved.
• a continuing or repeated dose regimen can also be used to achieve or maintain the desired result. Any other techniques known in the art can be used as well in determining the effective amount range.
• the specific effective amount will vary with such factors as the particular disease state being treated, the physical condition of the subject, the type of animal being treated, the duration of the treatment, route of administration, and the nature of any concurrent therapy.
• positive or negative changes in the subject's heart function during or following treatment may be determined by any measure known to those of skill in the art including, without limitation, measuring end systolic pressure, measuring end diastolic pressure, measuring end diastolic volume, measuring end systolic volume, measuring cardiac ejection fraction, measuring cardiac output, measuring contractility (end systolic pressure volume relationship, stroke work or preload recruitable stroke work), and measuring infarct size.
• the disclosed injectable compositions may include one or more fragments of the engineered CF-ECMs and a population of educated macrophages, along with an injectable pharmaceutically-acceptable carrier, where the fragments of the CF-ECM are sufficiently small to be able to freely pass through a hypodermic needle opening.
• Methods of making the engineered CF-ECM and information regarding its use in injectable compositions are disclosed in, for example, U.S. Patent No. 8,802,144 and U.S. Patent Publication No. US 2016/0354447, both of which are incorporated herein by reference.
• cardiac specific educated macrophages are administered with an injectable CF-ECM in a treatment in which the CF-ECM is administered prior to macrophage administration to provide an in situ niche for macrophage engraftment, retention and functionality.
• the CF-ECM is administered simultaneously in a single composition with the macrophages.
• the CF-ECM is infused or implanted with tissue-specific extracellular factors prior to use as a carrier for the educated macrophages.
• the injectable composition may be used to treat cardiac disease or injury, ischemic limb injury, or other injury due to the interruption of blood supply to a tissue.
• the injectable composition is delivered into an endocardial wall of a heart chamber using any appropriate means for trans-endocardial delivery.
• a delivery catheter can be used to deliver the injectable composition for treatment of a cardiac disease or condition.
• Other delivery devices can be used to achieve therapeutic or diagnostic delivery of an injectable composition as described herein.
• the injectable composition can be delivered using a cardiac needle tip injection catheter such as the Myostar (Biosense Webster), Helix (Biocardia), Bullfrog (Mercator MedSystems) or C-Cath (Cardio3Biosciences).
• delivery of an injectable composition by the injection methods described herein is minimally invasive and can be achieved without general anesthesia, extracorporeal circulation (e.g., circulation via a heart-lung machine), circulatory support, or a chest opening. Accordingly, complication prospects and risks to the patient are substantially lower.
• the injectable composition is delivered to the outer heart wall (epicardium) using any appropriate means for epicardial delivery.
• epicardial delivery of an injectable composition described herein can be achieved using a delivery device comprising a needle and/or syringe.
• a suitable delivery vehicle may be cardiac fibroblast derived extracellular matrix.
• a suitable delivery vehicle may be cardiac fibroblast derived extracellular matrix embedded with cardiac fibroblast exosomes.
• the donor and the recipient of the educated macrophages can be a single individual or different individuals, for example, allogeneic or xenogeneic individuals.
• allogeneic refers to something that is genetically different although belonging to or obtained from the same species (e.g., allogeneic tissue grafts or organ transplants). "Xenogeneic” means the cells could be derived from a different species.
• CF-EEM Cardiac Fibroblast Exosome-Educated Macrophages
• BM-MSC bone marrow mesenchymal stem cells
• CF cardiac fibroblasts
• CF-ECM cardiac fibroblast-derived extracellular matrix
• human CF-EEMs are generated by co-culturing macrophages with cardiac fibroblast-derived exosomes and subsequently administered into immunocompromised rats that have undergone coronary artery ligation to induce a large MI. Ejection fraction, infarct size, pressure-volume hemodynamics, angiogenic responses, fibro- healing responses, and CF-EEM retention are measured.
• Red blood cells were lysed by incubating cells in ACK lysis buffer (Lonza, Walkersville, MD) for 3 minutes and mononuclear cells were washed with phosphate-buffered saline (PBS). To reduce platelet contamination, cell suspensions were centrifuged at 300-700 rpm for 10 minutes and cell pellets were re-suspended in autoMACSTM running buffer (Miltenyi Biotec, cat # 130-091-221). To isolate monocytes, the cells were incubated with anti-human CD14 microbeads (Miltenyi Biotech, Auburn, CA, USA) for 15 minutes at 4°C. After washing to remove unbound antibody, cell separation was done using autoMACSTM Pro Separator (Miltenyi Biotech).
• CD14 + monocytes were plated either into six-well cell culture plates for flow cytometry or in 75-cm 2 filter cap cell culture flask (Greiner Bio-One, Monroe, NC, USA) for exosome isolation or in vitro assays at a concentration of 0.5-1 x 10 6 per well or flask in Iscove's modified Dulbecco's medium (IMDM) without phenol (Gibco Life Technologies/ThermoFisher Scientific, Grand Island, NY ) supplemented with 10% human serum blood type AB (Mediatech, Herndon, VA, USA), l x nonessential amino acids (Lonza, Walkersville, MD, USA), 1 mM sodium pyruvate (Mediatech), and 4 ⁇ g/mL recombinant human insulin (Invitrogen).
• IMDM Iscove's modified Dulbecco's medium
• MSCs Mesenchymal stem cells
• Red blood cells were lysed with 3-minute incubation in ACK lysis buffer and mononuclear cells were suspended in a- Minimum Essential Medium (Corning CellGro, Manassas, VA) supplemented with 10% fetal bovine serum (FBS)(US origin, uncharacterized; Hyclone, Logan, UT, USA), l x nonessential amino acids, and 4 mM L-glutamine (Invitrogen, Carlsbad, CA, USA). Cells were cultured in 75-cm 2 filter cap cell culture flasks.
• FBS fetal bovine serum
• Cells (passage 0) were harvested by removing medium, washing with phosphate-buffered saline (PBS) then using TrypLETM cell dissociation enzyme (Invitrogen) to detach the adherent cells and then re-plated into new flasks.
• PBS phosphate-buffered saline
• TrypLETM cell dissociation enzyme Invitrogen
• Tissue collection protocols have been reviewed and approved by the UW School of Medicine and Public Health institutional review board (IRB).
• Cadaveric cardiac tissue was harvested from recently deceased brain-dead donors at the University of Wisconsin-Madison Hospital & Clinics (UWHC) in Madison, Wisconsin under aseptic surgical conditions by the UW Organ Procurement Organization (OPO) and delivered to the investigators for cardiac fibroblast isolation.
• UWHC University of Wisconsin-Madison Hospital & Clinics
• OPO UW Organ Procurement Organization
• Cardiac fibroblasts were isolated from a modified protocol previously described. Briefly, hearts were obtained by the UWHC OPO using aseptic technique. Upon receipt, the fresh organ was removed from the transport container and the sterile packaging opened in a biological safety cabinet. 20-200 grams of left ventricle was dissected out. The dissected tissue was then coarsely chopped and 5-6 grams processed in gentleMACSTM C tubes (MACS Miltenyi Biotech/130-093-235). The tissue was then run through a standard cardiac dispersion protocol on the Miltenyi gentleMACSTM Dissociator.
• Clarified supernatant culture medium was then centrifuged in a Beckman Coulter OptimaTM L-80XP Ultracentrifuge at 100,000 g average at 4°C for 2 hours with a SW 28 rotor to pellet exosomes. The supernatant was carefully removed, and EV-containing pellets were re-suspended PBS and pooled. Typically we re-suspended the EV pellet at 100 ⁇ PBS/ 10 ml of CM.
• Cardiac fibroblast exosome characterization Cardiac fibroblast exosomes were characterized using a Thermo NanoDrop spectrophotometer for protein determination and approximate RNA concentration by direct absorbance; exosomes were not lysed, stained, or RNA extracted prior to measurements. Particle diameter and concentration were assessed by tunable resistive pulse sensing (TRPS; (qNano, Izon Science Ltd) using a NP150 nanopore membrane at a 47 mm stretch. The concentration of particles was standardized using multi- pressure calibration with 1 10 nm carboxylated polystyrene beads at a concentration of 1.1 x 10 13 particles/mL. The results of the CF exosome characterization are shown in FIG. 16.
• Exosome total RNA isolation - Exosomes from the cardiac fibroblasts were processed for total RNA isolation using the SeraMir Exosome RNA Purification Column kit (Cat #RA808A-1, System Biosciences, Palo Alto, CA) according to the manufacturer' s instructions. For each sample, 1 ⁇ of the final RNA eluate was used for measurement of small RNA concentration by Agilent Bioanalyzer Small RNA Assay using Bioanalyzer 2100 Expert instrument (Agilent Technologies, Santa Clara, CA).
• the size-selected library is quantified with High Sensitivity DNA 1000 Screen Tape (Agilent Technologies, PO # 5067-5584), High Sensitivity D1000 reagents (Agilent Technologies, PO# 5067-5585), and the TailorMix HTl qPCR assay (SeqMatic, Cat# TM-505), followed by a NextSeq High Output single-end sequencing run at SR75 using NextSeq 500/550 High Output v2 kit (Cat #FC-404-2005, Illumina, San Diego, CA) according to the manufacturer's instructions.
• RSEM Read Only Memory
• per gene expected counts in each sample were estimated using RSEM.
• cells were educated in either 6 well plates (2 ml) or 75-cm 2 filter cap cell culture flasks (10 ml) using either 60 ⁇ or 300 ⁇ of EVs respectively.
• Cell were harvested by removing the medium, washing with phosphate-buffered saline (PBS) then using TrypLETM cell dissociation enzyme (Invitrogen) and/or a cell scraper.
• PBS phosphate-buffered saline
• TrypLETM cell dissociation enzyme Invitrogen
• Flow cytometry- Macrophages, MEMs or EV educated macrophages (EEMs) at day +10 of culture were collected, counted and incubated with Fc block (BD Pharmingen, cat#: 564220) and stained at 4°C for 20 minutes in antibody diluent (PBS with 2% FBS) with anti- human antibodies including PE-Cy7-CD90 (5E10, cat# 328124), FITC-CD163 (GHI/61, cat# 333618), FITC-CD39 (Al, cat# 328206), PE-CD206 (15-2, cat# 321106), PerCP/Cy5.5-CD14 (HCD14, cat# 325622, APC-PD-L1 (29E.2A3, cat# 329708), APC-PD-L2 (24F.10C12, cat# 329608), Pacific Blue-HLA- DR/MHC II (L234, cat# 307633), BV421-CD16 (3G
• Ct threshold cycle
• Activated T-cell suppression assay The activated T-cell suppression assay was performed in 48 well tissue culture plates. Frozen stocks of peripheral blood mononuclear cells (PBMCs) containing T cells and MSCs, macrophages and BM-EEMs were freshly cultivated in medium (IPA medium) consisting of RPMI-1640 containing 10% heat inactivated FBS, l x nonessential amino acids (NEAA) (Mediatech, Inc., Manassas, VA), l x Glutamine (Mediatech, Inc.), IX Na Pyruvate (Sigma-Aldrich), and l x HEPES buffer (Sigma-Aldrich,, St. Louis, MO).
• IPA medium consisting of RPMI-1640 containing 10% heat inactivated FBS, l x nonessential amino acids (NEAA) (Mediatech, Inc., Manassas, VA), l x Glutamine (Mediatech, Inc.), IX Na Pyruvate
• PBMCs were first labeled with carboxyfluorescein succinate-ester (CFSE) at a final concentration of luM for 10 minutes, at 37 °C in the dark, mixing at the 5 minute time point to ensure homogeneous labeling. An equal volume of cold FBS was added for 1 minute to stop the CFSE labeling reaction. PBMCs were then washed twice with IPA medium before reconstitution at 4 ⁇ 10 6 /ml. One hundred microliters (4 10 5 ) of CFSE-labeled PBMCs was added to each well containing MSCs, macrophages and BM-EEMs.
• CFSE carboxyfluorescein succinate-ester
• Ratios of antibody- activated PBMCs to MSC, macrophages and BM-EEMs evaluated in this assay include 1 :0 (positive control-no suppression), 1 : 1, 1 :0.5, 1 :0.2, 1 :0.1, and 1 :0.05.
• MSCs were included in this assay to serve as a positive control cell group because MSCs are known to strongly inhibit PBMC proliferation.
• PBMC:MSC 4 x 10 5 MSCs (100 ⁇ ) were plated and then titrated further to 2 l O 4 to achieve a 1 :0.05 (PBMC:MSC) ratio.
• non-activated control consisting of a 1 :0.05 PBMC: MSC cell ratio without the addition of activation antibodies (anti-CD3 and anti-CD28) (negative control-no T-cell activation).
• PBMC MSC PBMC macrophages
• PBMC:BM-EEMs PBMC macrophages
• PBMC:BM-EEMs PBMC macrophages
• PBMC:BM-EEMs peripheral blood cells
• the PBMCs in the cell mixture were then activated with anti-CD3 and anti-CD28 antibodies (clones UCHT1 and 37407, respectively) (R&D Systems, Inc., Minneapolis, MN).
• PBMC:MSC 1 :0.05
• IPA medium 100 ⁇ of IPA medium for a total volume of 400 ⁇ per well.
• the cell mixture was cultured for 4 days at 37 °C with 5% C02.
• the PBMCs were recovered from each well by pipetting up and down to mix and added to a 5 ml flow tube.
• CD4+ T helper cells and CD8+ cytotoxic cells were each analyzed for proliferation using standard flow cytometry methodology.
• Anti-human APC -CD4 or CD8- was used to gate the T-cell types. All proliferation analyses were performed using an Accuri C6 flow cytometer (BD Biosciences, Inc., San Jose, CA) and the associated C6 Plus software was used for the CFSE analysis.
• Exosomes were isolated from human bone marrow mesenchymal stem cells and human cardiac fibroblasts and characterized for particle size (diameter), protein and RNA concentration and exosome concentrations (FIGS. 2A-2B, Table 2). We found that exosomes derived from MSCs and cardiac fibroblasts were different in diameter and protein/RNA concentration. In general, cardiac fibroblast-derived exosomes were larger than MSC-derived exosomes, but had less protein and RNA. Sample transmission electron microscopy images of exosomes derived from mesenchymal stem cells (FIG. 3A) and cardiac fibroblasts (FIG. 3B) were taken. Additionally, functionality testing of the MSC-derived exosomes (FIGS. 4A-4B) shows the exosomes are functional and capable of lipophilic dye transfer into endothelial cells.
• Table 2 Characterization by IZON qNano System of exosomes generated from multiple sources
• Human cardiac fibroblasts were characterized by flow cytometry and compared to MSCs and dermal fibroblasts. As depicted in FIG. 15, human cardiac fibroblasts differentially express CD90, CD34, SUSD2, w67C, and TNAP compared to either BM-MSCs or dermal fibroblasts. In addition, cardiac fibroblasts also express GATA 4, which is not expressed in MSCs or dermal fibroblasts.
• FIGS. 5A-5J Following co-culture of macrophages with bone marrow-MSC exosomes or cardiac fibroblast exosomes, expression profiles and phenotypes of the educated macrophages were analyzed as depicted in FIGS. 5A-5J.
• Canonical M2 macrophage surface markers were examined by flow cytometry. Significant difference was found in both surface marker percentages and fluorescence intensity of the markers.
• exosome education results in significant difference among bone marrow MSC (BM-MEM), BM-EEM and CF-EEM groups.
• BM-MEM bone marrow MSC
• BM-EEM bone marrow EOM
• CF-EEM groups Importantly, bone marrow exosome- and cardiac fibroblast exosome-educated macrophages display different phenotypes.
• exosomes isolated from macrophage cultures were used in co-culture with CD14 + cells but were unable to induce an antiinflammatory phenotype in the educated macrophages, and displayed the same surface marker phenotype as the untreated control macrophages, thus showing that the anti-inflammatory phenotype education is unique to tissue-specific (i.e., MSC or CF) exosomes (FIGS. 7A-7E)
• Ml (inflammatory) macrophage surface markers in the educated macrophages were examined by flow cytometry, as depicted in FIGS. 6A-6D. Significant difference was found in both surface marker percentages and fluorescence intensity of the markers. Specifically, exosome education results in significant difference among bone marrow MSC (BM-MEM), BM- EEM and CF-EEM groups. Bone marrow and cardiac fibroblast exosome educated antiinflammatory macrophages have reduced Ml markers compared to macrophages generated by co-cultivation with bone marrow MSCs.
• CD206 a specific marker for M2 macrophages was assayed by flow cytometry (FIG. 8) in uneducated macrophages (control) and compared to macrophages that were educated either by co-cultivation with cells, (MSCs (BM-MSC co-culture) or cardiac fibroblasts (cardiac fibroblasts co-culture)) with exosomes, (from either BM-MSCs (BM-MSC exosome) or CFs (CF exosome) or with extracted ECM from a CF culture (CF-ECM culture).
• flow cytometry FOG. 8
• TGF- ⁇ , IL-10 immune-modulatory cytokines
• IL-lb immune-modulatory cytokines
• PD-L1 immunosuppressive molecules
• EEMs educated using exosomes isolated from BM-MSCs could effectively suppress antibody induced T-cell proliferation in both T-helper cells (A) and T-cytotoxic cells (B) subtypes when compared to uneducated control macrophages (Macrophages) (FIGS. 11A and 1 IB).
• MSCs Serving as a positive control for suppression, MSCs could effectively suppress the percent of T cell proliferation on both subtypes.
• a dose response at a PBMC to MSCs ratio of 1 : 1 to 1 :0.05 is seen with complete suppression at 1 : 1 and approximately 30 to 35% proliferation (or essentially 65 to 70% growth suppression) at a ratio as low as 1 :0.05.
• CF-EEMs have a unique secretome compared to non-stimulated macrophages and bone marrow-MSC EEMs (BM-EEM).
• BM-EEMs secrete EGF, compared to control macrophages (PBS) or BM-EEMS while BM-EEMs secrete significantly more GRO compared to CF-EEMs and control macrophages.
• Macrophages cultured on cardiac fibroblast derived extracellular matrix have a unique anti-inflammatory phenotype.
• CF-ECM-EMs have significantly lower expression of CD86 and ULA-DR, while PDL-1 expression is significantly increased.
• PDL-1 is believed to play a major role in suppressing the immune system.
• human macrophages were cultured on plastic, gelatin or CF-ECM for 3 days then removed from the surfaces and flow cytometry used to analyze surface marker expression.
• CF-ECM educated macrophages had a significantly higher expression (by mean fluorescent intensity) of CD 14, CD 163, CD206 and PDL as compared to macrophages cultured on plastic or gelatin.
• CF-ECM-EM had significantly lower expression of inflammatory markers CD68 and ULA-DR as compared to macrophages cultured on plastic or gelatin. This data shows that CF-ECM education of CD14 + cells generates macrophages which are phenotypically different than CD 14+ cells grown using commonly used methods for coating culture plates.
• Cardiac fibroblast exosome-educated macrophages were transplanted into infarcted rat hearts using injectable cardiac fibroblast-derived extracellular matrix as a carrier.
• Animals treated with CF-EEMs showed a significant reduction in ventricular dilation (reduced end systolic and diastolic volumes) and a trend toward increased end systolic pressures (FIGS. 12A-12E) Most importantly, end systolic pressure volume relationship (ESPVR), the gold standard measurement for cardiac contractility, was significantly improved in CF-EEM treated animals. Taken together, CF-EEM treatment blunts deleterious post-MI cardiac remodeling and improves cardiac contractility.
• ESPVR end systolic pressure volume relationship
• a patient suffering from myocardial infarction or ischemic heart failure is treated as follows: i) biopsy sufficient heart tissue from sick heart failure patients and expand the CFs into large quantities in culture, or isolate the CFs from healthy donor hearts that were not used for heart transplant instead of biopsy specimens from the patients themselves; (This cell harvesting method is currently used by a biotech company called Capricor Inc.
• Leukapheresis is a highly efficient and safe procedure to obtain large quantities of mononuclear cells including monocytes and simply uses two IVs in each arm vein. Leukapheresis has been used for decades to harvest cells for hematopoietic reconstitution, and it also has been used safely for numerous advanced cardiovascular disease trials including those by Raval et al.
• a major advantage with our approach includes the ability to administer well-defined doses of CF exosome-educated macrophages (CF-EEM) to the patient.
• CF-EEM CF exosome-educated macrophages
• Macrophages have an important role in tissue repair in response to ischemic, traumatic, inflammatory injury, and the normal aging process.
• pro-regenerative macrophages are "switched on” or “polarized” from monocytes that reside in the bone marrow, circulation and tissues.
• this innate repair response is inadequate as the tissue may be overwhelmed by the sheer magnitude of the tissue injury.
• tissue source such as fibroblasts, tissue progenitor cells and others are harvested using aspiration, biopsy or organ procurement or differentiated from pluripotent stem cells, such as embryonic stem cells or induced pluripotent stem cells (B).
• pluripotent stem cells such as embryonic stem cells or induced pluripotent stem cells (B).
• Tissue-specific cells or extracellular factors, such as exosomes, micro-vesicles, and extracellular matrix, derived from the tissue-specific cells C
• monocytes or macrophages to generate tissue-specific educated macrophages (D) that have pro-reparative, angiogenic, anti-inflammatory, and immunomodulatory phenotypes favorable to those specific tissues.
• Tissue-specific educated macrophages are expected to be phenotypically and functionally unique with unique cytokine, RNA, surface marker and functional expression. These tissue-specific educated macrophages can be delivered to a subject in need of treatment systemically or directly into injured tissues. Methods of delivery can include intravenous infusion, intravascular infusion, percutaneous injection, surgical injection, topical administration or any other delivery method described herein. Tissue-specific educated macrophages are expected to restore injured tissues as demonstrated in a variety of animal models (E) and clinical applications (F) in a tissue-specific manner.
• E animal models
• F clinical applications
• pulmonary fibroblasts, pneumocytes, or dust cells are obtained by biopsy or differentiation of pluripotent stem cells. Pulmonary fibroblasts, pneumocytes, or dust cells or their extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate lung-specific educated macrophages. These lung specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the lung-specific educated macrophages are administered to a subject, such as to recover or repair lung function in a rat inflammatory lung injury model and in humans with smoke inhalational lung injury, COPD, asthma, pulmonary fibrosis, or bronchiolitis obliterans.
• skin stromal cells such as keratinocytes or dermal fibroblasts are obtained by biopsy or differentiation of pluripotent stem cells. Skin cells or skin cell extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate skin specific educated macrophages. These skin-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the skin-specific educated macrophages are administered to a subject, such as to heal a wound or burn in an animal skin injury model and in humans with burns, trauma, inflammatory skin disorders such as psoriasis, skin GVHD, systemic scleroderma, ischemic ulcers or neuropathic ulcers.
• pancreatic stromal cells such as MSCs in the pancreas, pancreatic stromal or fibroblast cells, or pancreatic islet cells, are obtained by biopsy or differentiation of pluripotent stem cells.
• Pancreatic cells or pancreatic cell extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate pancreas- specific educated macrophages.
• These pancreas-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the pancreas-specific educated macrophages are administered to a subject, such as to recover or repair pancreas function in an animal pancreas disease model, such as genetic knockouts or excess caloric intake models, and in humans with diabetes.
• liver cells such as hepatocytes, Kuppfer cells, hepatic fibroblasts or MSCs, are obtained by biopsy or differentiation of pluripotent stem cells. Liver cells or liver cell extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate liver-specific educated macrophages. These liver-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages. The liver-specific educated macrophages are administered to a subject, such as to recover or repair liver function in an animal model of cirrhosis and in humans with cirrhosis or liver failure.
• a subject such as to recover or repair liver function in an animal model of cirrhosis and in humans with cirrhosis or liver failure.
• kidney cells such as MSCs, fibroblasts, glomerular cells, tubular cells, podocytes or mesangial cells
• Kidney cells or kidney cell extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate kidney-specific educated macrophages.
• These kidney-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• kidney-specific educated macrophages are administered to a subject, such as to recover or repair kidney function in an animal model of acute or chronic renal failure and in humans with acute or chronic renal failure, end stage renal disease, glomerulonephritis, and lupus nephritis.
• brain cells such as glial cells
• brain cells are obtained by biopsy or differentiation of pluripotent stem cells.
• Brain cells or brain cell extracellular factors are co- cultured with circulating monocytes obtained through leukapheresis to generate brain-specific educated macrophages.
• These brain-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the brain-specific educated macrophages are administered to a subject, such as to recover or repair brain function in a rat or mouse stroke model and in humans with stroke, neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's disease, or neurodevelopmental disease.
• cells from endocrine organs are obtained by biopsy or differentiation of pluripotent stem cells.
• Endocrine fibroblasts or stromal cells, or their extracellular factors are co-cultured with circulating monocytes obtained through leukapheresis to generate endocrine-specific educated macrophages.
• monocytes obtained through leukapheresis to generate endocrine-specific educated macrophages.
• These endocrine-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the endocrine-specific educated macrophages are administered to a subject, such as to recover or repair endocrine function in an animal model of hormone deficiency and in humans with hormone deficiency or inflammation of the endocrine organ.
• Example 10 Prophetic
• reproductive organs such as Leydig cells, MSCs and other stromal cells
• reproductive organs are obtained by biopsy or differentiation of pluripotent stem cells.
• Cells from reproductive organs or extracellular factors derived therefrom are co-cultured with circulating monocytes obtained through leukapheresis to generate reproductive organ-specific educated macrophages.
• These reproductive organ-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the reproductive organ-specific educated macrophages are administered to a subject, such as to recover or repair reproductive organ function in an animal model of infertility and in humans with infertility, hormonal imbalance, injury to a reproductive organ, menopause or normal aging reproductive hormonal deficiency such as low testosterone levels.
• vascular cells such as pericytes or endothelial cells
• vascular-specific educated macrophages have a unique differential cytokine, growth factor, protein and RNA expression profile compared to traditional Ml or M2 macrophages or other tissue-specific macrophages.
• the vascular-specific educated macrophages are administered to a subject, such as to recover or repair vascular function in an animal model of vein or artery ligation and in humans with peripheral artery disease.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Cell Biology (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Developmental Biology & Embryology (AREA)
• Organic Chemistry (AREA)
• Hematology (AREA)
• Virology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Dermatology (AREA)
• Gastroenterology & Hepatology (AREA)
• Cardiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Engineering & Computer Science (AREA)
• Urology & Nephrology (AREA)
• Heart & Thoracic Surgery (AREA)
• Microbiology (AREA)
• Vascular Medicine (AREA)
• Biochemistry (AREA)
• Botany (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58548819

Family Applications (1)

Country Status (7)

Cited By (4)

Families Citing this family (7)

Citations (5)

Family Cites Families (4)

• 2018
  • 2018-03-30 WO PCT/US2018/025371 patent/WO2018183825A1/en not_active Ceased
  • 2018-03-30 US US15/941,409 patent/US11760975B2/en active Active
  • 2018-03-30 CA CA3058437A patent/CA3058437A1/en active Pending
  • 2018-03-30 AU AU2018243554A patent/AU2018243554C1/en active Active
  • 2018-03-30 DK DK18720454.0T patent/DK3600354T3/da active
  • 2018-03-30 EP EP18720454.0A patent/EP3600354B1/en active Active
  • 2018-03-30 JP JP2019553818A patent/JP7249951B2/ja active Active
• 2022
  • 2022-12-22 JP JP2022205718A patent/JP7419490B2/ja active Active
• 2023
  • 2023-08-17 US US18/451,617 patent/US20230407256A1/en active Pending

Patent Citations (6)

Non-Patent Citations (48)

Also Published As

Similar Documents

Legal Events